Companion Diagnostics
News on companion diagnostics and drug/test co-development.
Agilent Obtains CE-IVD Mark for CDx to ID Cervical Cancer Patients Suitable for Keytruda
The assay can be used as an aid to identify cervical cancer patients for whom treatment with the anti-PD-1 therapy Keytruda may be appropriate.
NGeneBio Receives CE-IVD Mark for NGS-Based Cancer Panel
The firm's accompanying software analyzes companion diagnostic biomarkers such as EGFR, BRAF, KRAS, HER2, and ROS1 genes.
Illumina, Janssen Biotech Form Strategic Partnership to Develop Precision Medicines
The collaboration aims to utilize the sequencing giant's data analytics platforms and lab services to speed up the development of personalized therapies.
AmoyDx, AstraZeneca Collaborate to Develop, Commercialize Companion Diagnostic Tests
The agreement involves the codevelopment of a CDx to identify prostate cancer patients in China, the European Union, and Japan with HRR gene mutations.
Agilent Expands CE-IVD Mark for Companion Dx Tests Alongside BMS European Opdivo Approvals
Agilent obtained a CE-IVD mark for expanded use of its PD-L1 IHC 28-8 pharmDx assay to guide cancer treatment with Bristol Myers Squibb's Opdivo.